



A



B



C




Figure S1. Schematic and characterization of VSV-based vaccines. (A) Schematic illustrating vaccine vector design. T7 promoter; N nucleoprotein; P phosphoprotein; M matrix protein; EBOV GP Ebola virus glycoprotein; L RNA-dependent RNA polymerase; SARS2-S full-length SARS-CoV-2 S. (B) Western blot analysis of cell supernatant samples containing VSV vaccines probed for SARS-CoV-2 S (left), VSV M (right) or EBOV GP (right). Lane 1 wildtype VSV; lane 2 VSV-EBOV; lane 3 VSV-SARS2-EBOV. (C) Viral growth kinetics performed in triplicates on VeroE6 cells. Geometric mean and SD are depicted.